High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 266-277

  Brochu, I ^a   Houde, M ^a   Desbiens, L ^a   Simard, E ^a   Gobeil, F ^a   Semaan, W ^a   Bkaily, G ^a   D'Orleans Juste P ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

A127722; bradykinin; ET 1; high salt diet; knockout mice; radiotelemetry; RIA

Indexed keywords

4 (1,3 BENZODIOXOL 5 YL) 1 [(2,6 DIETHYLPHENYL)CARBAMOYLMETHYL] 2 (4 PROPOXYPHENYL) 3 PYRROLIDINECARBOXYLIC ACID; ATRASENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MESSENGER RNA; POTASSIUM; SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; ELECTROLYTE EXCRETION; FEMALE; HEART RATE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TISSUE DISTRIBUTION;

A127722; BRADYKININ; ET-1; HIGH-SALT DIET; KNOCKOUT MICE; RADIOTELEMETRY; RIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FEMALE; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NG-NITROARGININE METHYL ESTER; PEPTIDES, CYCLIC; PYRROLIDINES; RECEPTOR, BRADYKININ B2; RECEPTOR, ENDOTHELIN A; SODIUM; SODIUM CHLORIDE, DIETARY; TELEMETRY;

EID: 84883212176     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12259     Document Type: Article

References (62)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Alfie ME, Yang XP, Hess F, Carretero OA, (1996). Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224: 625-630.
3. Amiri F, Ko EA, Javeshghani D, Reudelhuber TL, Schiffrin EL, (2010). Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice. J Hypertens 28: 1243-1251.
4. Andrade D, Serra R, Svensjo E, Lima AP, Ramos ES Jr, Fortes FS, et al. (2012). Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy. Br J Pharmacol 165: 1333-1347.
5. Ashizawa N, Okumura H, Matsuura A, Kobayashi F, (1994). Diltiazem facilitates endothelin clearance from the blood stream to reduce toxic elevation of plasma endothelin level in rodents. J Pharm Pharmacol 46: 200-204.
6. Berthiaume N, Hess F, Chen A, Regoli D, D'Orleans-Juste P, (1997). Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. Eur J Pharmacol 333: 55-61.
7. Berthiaume N, Yanagisawa M, Labonte J, D'Orleans-Juste P, (2000). Heterozygous knock-out of ETB receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 36: 1002-1007.
8. Bolli MH, Boss C, Binkert C, Buchmann S, Bur D, Hess P, et al. (2012). The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]- 4-pyrimidinyl]-N'-p ropylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55: 7849-7861.
9. Borkowski JA, Hess JF, (1995). Targeted disruption of the mouse B2 bradykinin receptor in embryonic stem cells. Can J Physiol Pharmacol 73: 773-779.
10. Boulanger SC, Glick PL, (2000). Positive end expiratory pressure and response to inhaled nitric oxide therapy. Surgery 128: 871-872.
11. Boyce S, Rupniak NM, Carlson EJ, Webb J, Borkowski JA, Hess JF, et al. (1996). Nociception and inflammatory hyperalgesia in B2 bradykinin receptor knockout mice. Immunopharmacology 33: 333-335.
12. Butz GM, Davisson RL, (2001). Long-term telemetric measurement of cardiovascular parameters in awake mice: a physiological genomics tool. Physiol Genomics 5: 89-97.
13. Carlson SH, Wyss JM, (2000). Long-term telemetric recording of arterial pressure and heart rate in mice fed basal and high NaCl diets. Hypertension 35: E1-E5.
14. Carr MJ, Spalding LJ, Goldie RG, Henry PJ, (1998). Distribution of immunoreactive endothelin in the lungs of mice during respiratory viral infection. Eur Respir J 11: 79-85.
15. Cervenka L, Harrison-Bernard LM, Dipp S, Primrose G, Imig JD, El-Dahr SS, (1999). Early onset salt-sensitive hypertension in bradykinin B(2) receptor null mice. Hypertension 34: 176-180.
16. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358: 1119-1123.
17. Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, et al. (2007). Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 334: 885-888.
18. D'Orleans-Juste P, Labonte J, Bkaily G, Choufani S, Plante M, Honore JC, (2002). Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther 95: 221-238.
19. Dhaun N, Pollock DM, Goddard J, Webb DJ, (2007). Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 28: 573-579.
20. Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H, (2001). Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 88: 275-281.
21. Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL, (2001). Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 103: 263-268.
22. Ergul A, (2000). Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 36: 62-67.
23. Ergul S, Ergul A, Hudson JA, Puett D, Wieman BM, Durham MD, et al. (1998). The effect of regulation of high blood pressure on plasma endothelin-1 levels in blacks with hypertension. Am J Hypertens 11 (11 Pt 1): 1381-1385.
24. Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, et al. (2000). Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens 13: 1268-1273.
25. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M, (2000). Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105: 925-933.
26. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, et al. (2006). Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274-F1280.
27. von Geldern TW, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, Dixon DB, et al. (1999). Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem 42: 3668-3678.
28. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al. (1993). Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328: 1732-1739.
29. Gratton J, Rae G, Bkaily G, D'Orléans-Juste P, (2000). ET(B) receptor blockade potentiates the pressor response to big endothelin-1 but not big endothelin-2 in the anesthetized rabbit. Hypertension 35: 726-731.
30. Gratton JP, Cournoyer G, Loffler BM, Sirois P, D'Orleans-Juste P, (1997). ET(B) receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension 30: 1204-1209.
31. Grim CE, Robinson M, (1996). Blood pressure variation in blacks: genetic factors. Semin Nephrol 16: 83-93.
32. Helms MN, Yu L, Malik B, Kleinhenz DJ, Hart CM, Eaton DC, (2005). Role of SGK1 in nitric oxide inhibition of ENaC in Na+-transporting epithelia. Am J Physiol Cell Physiol 289: C717-C726.
33. Honore JC, Fecteau MH, Brochu I, Labonte J, Bkaily G, D'Orleans-Juste P, (2005). Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster. Am J Physiol Heart Circ Physiol 289: H1258-H1264.
34. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, et al. (1992). Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 50: 247-255.
35. Kakoki M, McGarrah RW, Kim HS, Smithies O, (2007). Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 104: 7576-7581.
36. Katori M, Majima M, (2006). A missing link between a high salt intake and blood pressure increase. J Pharmacol Sci 100: 370-390.
37. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
38. Kohan DE, (2011). Endothelin and collecting duct sodium and water transport. Contrib Nephrol 172: 94-106.
39. 2 receptors in the ex vivo platelet inhibitory properties of endothelin and bradykinin in the mouse. Br J Pharmacol 132: 934-940.
40. Loiola RA, Reis FC, Kawamoto EM, Scavone C, Abdalla DS, Fernandes L, et al. (2011). Role of vascular Kinin B1 and B2 receptors in endothelial nitric oxide metabolism. Peptides 32: 1700-1705.
41. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, et al. (1997). Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96: 3570-3578.
42. Mamenko M, Zaika O, Doris PA, Pochynyuk O, (2012). Salt-dependent inhibition of epithelial Na+ channel-mediated sodium reabsorption in the aldosterone-sensitive distal nephron by bradykinin. Hypertension 60: 1234-1241.
43. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. (2011). Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70: 32-38.
44. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
45. Mulatero P, Williams TA, Milan A, Paglieri C, Rabbia F, Fallo F, et al. (2002). Blood pressure in patients with primary aldosteronism is influenced by bradykinin B(2) receptor and alpha-adducin gene polymorphisms. J Clin Endocrinol Metab 87: 3337-3343.
46. Nakano D, Pollock D, (2012). New concepts in endothelin control of sodium balance. Clin Exp Pharmacol Physiol 39: 104-110.
47. Okumura H, Ashizawa N, Kobayashi F, Arai K, Asakura R, Ashikawa N, et al. (1993). Comparison of haemoconcentration induced by big endothelin-1 and endothelin-1 in mice. Br J Pharmacol 110: 1395-1400.
48. Okumura H, Ashizawa N, Asakura R, Aotsuka T, Kobayashi F, Matsuura A, (1995). Possible involvement of different mechanisms in sudden death induced by endothelin-1 and big endothelin-1. Biol Pharm Bull 18: 18-23.
49. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, et al. (1996). Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 276: 473-481.
50. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S, (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752.
51. Samadfam R, Teixeira C, Bkaily G, Sirois P, de Brum-Fernandes A, D'Orleans-Juste P, (2000). Contribution of B(2) receptors for bradykinin in arthus reaction-induced plasma extravasation in wild-type or B(2) transgenic knockout mice. Br J Pharmacol 129: 1732-1738.
52. Sanders PW, (2009a). Dietary salt intake, salt sensitivity, and cardiovascular health. Hypertension 53: 442-445.
53. Sanders PW, (2009b). Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 297: F237-F243.
54. Schanstra JP, Duchene J, Praddaude F, Bruneval P, Tack I, Chevalier J, et al. (2003). Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284: H1904-H1908.
55. Seabrook GR, Bowery BJ, Heavens R, Brown N, Ford H, Sirinathsinghi DJ, et al. (1997). Expression of B1 and B2 bradykinin receptor mRNA and their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurones from wild-type and B2 receptor knockout mice. Neuropharmacology 36: 1009-1017.
56. Sirvio ML, Metsarinne K, Saijonmaa O, Fyhrquist F, (1990). Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun 167: 1191-1195.
57. Takeda M, Saito K, Tsutsui T, Mizusawa T, Obara K, Tomita Y, et al. (1997). Plasma endothelin-1 level in patients with renovascular hypertension-does the kidney with stenosis of the renal artery upregulate production of endthelin-1? Eur J Med Res 2: 315-320.
58. Tan Y, Keum JS, Wang B, McHenry MB, Lipsitz SR, Jaffa AA, (2007). Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 293: F1026-F1035.
59. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. (2009). A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374: 1423-1431.
60. Weir MR, Gray JM, Paster R, Saunders E, (1995). Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 26: 124-130.
61. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415.
62. Zaika O, Mamenko M, O'Neil RG, Pochynyuk O, (2011). Bradykinin acutely inhibits activity of the epithelial Na+ channel in mammalian aldosterone-sensitive distal nephron. Am J Physiol Renal Physiol 300: F1105-F1115.